Literature DB >> 19527737

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.

Jeannie Hwang1, Crista Adamson, David Butler, David R Janero, Alexandros Makriyannis, Ben A Bahr.   

Abstract

AIMS: This review posits that fatty acid amide hydrolase (FAAH) inhibition has therapeutic potential against neuropathological states including traumatic brain injury; Alzheimer's, Huntington's, and Parkinson's diseases; and stroke. MAIN
METHODS: This proposition is supported by data from numerous in vitro and in vivo experiments establishing metabolic and pharmacological contexts for the neuroprotective role of the endogenous cannabinoid ("endocannabinoid") system and selective FAAH inhibitors. KEY
FINDINGS: The systems biology of endocannabinoid signaling involves two main cannabinoid receptors, the principal endocannabinoid lipid mediators N-arachidonoylethanolamine ("anandamide") (AEA) and 2-arachidonoyl glycerol (2-AG), related metabolites, and the proteins involved in endocannabinoid biosynthesis, biotransformation, and transit. The endocannabinoid system is capable of activating distinct signaling pathways on-demand in response to pathogenic events or stimuli, thereby enhancing cell survival and promoting tissue repair. Accumulating data suggest that endocannabinoid system modulation at discrete targets is a promising pharmacotherapeutic strategy for treating various medical conditions. In particular, neuronal injury activates cannabinoid signaling in the central nervous system as an intrinsic neuroprotective response. Indirect potentiation of this salutary response through pharmacological inhibition of FAAH, an endocannabinoid-deactivating enzyme, and consequent activation of signaling pathways downstream from cannabinoid receptors have been shown to promote neuronal maintenance and function. SIGNIFICANCE: This therapeutic modality has the potential to offer site- and event-specific neuroprotection under conditions where endocannabinoids are being produced as part of a physiological protective mechanism. In contrast, direct application of cannabinoid receptor agonists to the central nervous system may activate CB receptors indiscriminately and invite unwanted psychotrophic effects. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19527737      PMCID: PMC2848893          DOI: 10.1016/j.lfs.2009.06.003

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  142 in total

1.  Genetic variation may influence obesity only under conditions of diet: analysis of three candidate genes.

Authors:  Jens Aberle; Jörg Flitsch; Nicola Alessia Beck; Oliver Mann; Philipp Busch; Philipp Peitsmeier; Frank Ulrich Beil
Journal:  Mol Genet Metab       Date:  2008-09-23       Impact factor: 4.797

2.  Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates.

Authors:  Zuzana Justinova; Regina A Mangieri; Marco Bortolato; Svetlana I Chefer; Alexey G Mukhin; Jason R Clapper; Alvin R King; Godfrey H Redhi; Sevil Yasar; Daniele Piomelli; Steven R Goldberg
Journal:  Biol Psychiatry       Date:  2008-09-23       Impact factor: 13.382

3.  Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia.

Authors:  Markus Schomacher; Harald D Müller; Clemens Sommer; Stefan Schwab; Wolf-Rüdiger Schäbitz
Journal:  Brain Res       Date:  2008-09-18       Impact factor: 3.252

4.  Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters.

Authors:  JodiAnne T Wood; John S Williams; Lakshmipathi Pandarinathan; Amber Courville; Melissa R Keplinger; David R Janero; Paul Vouros; Alexandros Makriyannis; Carol J Lammi-Keefe
Journal:  Clin Chem Lab Med       Date:  2008       Impact factor: 3.694

5.  The endocannabinoid system is modulated in response to spinal cord injury in rats.

Authors:  Daniel Garcia-Ovejero; Angel Arevalo-Martin; Stefania Petrosino; Fabian Docagne; Carlos Hagen; Tiziana Bisogno; Masahiko Watanabe; Carmen Guaza; Vincenzo Di Marzo; Eduardo Molina-Holgado
Journal:  Neurobiol Dis       Date:  2008-09-30       Impact factor: 5.996

6.  Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism.

Authors:  Giorgio Ortar; Tiziana Bisogno; Alessia Ligresti; Enrico Morera; Marianna Nalli; Vincenzo Di Marzo
Journal:  J Med Chem       Date:  2008-10-03       Impact factor: 7.446

7.  2-Arachidonoylglycerol elicits neuroprotective effects on excitotoxically lesioned dentate gyrus granule cells via abnormal-cannabidiol-sensitive receptors on microglial cells.

Authors:  Susanne Kreutz; Marco Koch; Charlotte Böttger; Chalid Ghadban; Horst-Werner Korf; Faramarz Dehghani
Journal:  Glia       Date:  2009-02       Impact factor: 7.452

8.  Selectivity of inhibitors of endocannabinoid biosynthesis evaluated by activity-based protein profiling.

Authors:  Heather S Hoover; Jacqueline L Blankman; Sherry Niessen; Benjamin F Cravatt
Journal:  Bioorg Med Chem Lett       Date:  2008-07-02       Impact factor: 2.823

9.  Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation.

Authors:  Ying Pei; Richard W Mercier; Jenine K Anday; Ganesh A Thakur; Alexander M Zvonok; Dow Hurst; Patricia H Reggio; David R Janero; Alexandros Makriyannis
Journal:  Chem Biol       Date:  2008-11-24

10.  N-acylphosphatidylethanolamine, a gut- derived circulating factor induced by fat ingestion, inhibits food intake.

Authors:  Matthew P Gillum; Dongyan Zhang; Xian-Man Zhang; Derek M Erion; Rachel A Jamison; Cheolsoo Choi; Jianying Dong; Marya Shanabrough; Hillary R Duenas; David W Frederick; Jennifer J Hsiao; Tamas L Horvath; Chun Min Lo; Pat Tso; Gary W Cline; Gerald I Shulman
Journal:  Cell       Date:  2008-11-28       Impact factor: 41.582

View more
  37 in total

1.  Alcohol Versus Cannabinoids: A Review of Their Opposite Neuro-Immunomodulatory Effects and Future Therapeutic Potentials.

Authors:  Madhavan P Nair; Gloria Figueroa; Gianna Casteleiro; Karla Muñoz; Marisela Agudelo
Journal:  J Alcohol Drug Depend       Date:  2015-01-23

2.  Equipotent inhibition of fatty acid amide hydrolase and monoacylglycerol lipase - dual targets of the endocannabinoid system to protect against seizure pathology.

Authors:  Vinogran Naidoo; David A Karanian; Subramanian K Vadivel; Johnathan R Locklear; JodiAnne T Wood; Mahmoud Nasr; Pamela Marie P Quizon; Emily E Graves; Vidyanand Shukla; Alexandros Makriyannis; Ben A Bahr
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

Review 3.  The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes.

Authors:  Javier Fernández-Ruiz
Journal:  Br J Pharmacol       Date:  2018-07-08       Impact factor: 8.739

Review 4.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

5.  Pharmacological tools to mobilise mesenchymal stromal cells into the blood promote bone formation after surgery.

Authors:  Tariq G Fellous; Andia N Redpath; Mackenzie M Fleischer; Sapan Gandhi; Samantha E Hartner; Michael D Newton; Moïra François; Suet-Ping Wong; Kate H C Gowers; Adam M Fahs; Daniel R Possley; Dominique Bonnet; Paula Urquhart; Anna Nicolaou; Kevin C Baker; Sara M Rankin
Journal:  NPJ Regen Med       Date:  2020-02-21

6.  Inhibitor of Endocannabinoid Deactivation Protects Against In Vitro and In Vivo Neurotoxic Effects of Paraoxon.

Authors:  Karen L G Farizatto; Sara A McEwan; Vinogran Naidoo; Spyros P Nikas; Vidyanand G Shukla; Michael F Almeida; Aaron Byrd; Heather Romine; David A Karanian; Alexandros Makriyannis; Ben A Bahr
Journal:  J Mol Neurosci       Date:  2017-08-12       Impact factor: 3.444

7.  Controlled-deactivation cannabinergic ligands.

Authors:  Rishi Sharma; Spyros P Nikas; Carol A Paronis; Jodianne T Wood; Aneetha Halikhedkar; Jason Jianxin Guo; Ganesh A Thakur; Shashank Kulkarni; Othman Benchama; Jimit Girish Raghav; Roger S Gifford; Torbjörn U C Järbe; Jack Bergman; Alexandros Makriyannis
Journal:  J Med Chem       Date:  2013-12-10       Impact factor: 7.446

8.  The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury.

Authors:  Flaubert Tchantchou; Laura B Tucker; Amanda H Fu; Rebecca J Bluett; Joseph T McCabe; Sachin Patel; Yumin Zhang
Journal:  Neuropharmacology       Date:  2014-06-14       Impact factor: 5.250

9.  Selective inhibition of alpha/beta-hydrolase domain 6 attenuates neurodegeneration, alleviates blood brain barrier breakdown, and improves functional recovery in a mouse model of traumatic brain injury.

Authors:  Flaubert Tchantchou; Yumin Zhang
Journal:  J Neurotrauma       Date:  2013-04-05       Impact factor: 5.269

10.  Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma.

Authors:  Jodianne T Wood; John S Williams; Lakshmipathi Pandarinathan; David R Janero; Carol J Lammi-Keefe; Alexandros Makriyannis
Journal:  J Lipid Res       Date:  2010-01-13       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.